Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00811122 · ClinicalTrials.gov registry record · Early Phase 1
Biodistribution of 11C-PIB PET in Alzheimer's Disease, Frontotemporal Dementia, and Cognitively Normal Elderly
A Early Phase 1 study, sponsored by University of Utah.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 2
- Enrollment target
NCT00811122 is a Early Phase 1 study that was terminated before completion, run by University of Utah. The registered enrollment target is 2 participants.
The verdict
NCT00811122, a Early Phase 1 study, was terminated before completion, sponsored by University of Utah.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
Alzheimer's disease (AD) is characterized by neuritic plaques, neurofibrillary tangles, and neuronal cell loss. Amyloid plaques are believed to play an integral role in AD. Elevated levels of Aβ in the brain are correlated with cognitive decline. There are no approved ways to measure amyloid load in humans. Several compounds are under investigation. All of these compounds use radioactive chemical tags for positron emission tomography (PET) imaging. The most promising compound is 11C-PIB, or Pittsburgh Compound-B. This compound can be injected and a PET scan performed. This allows doctors to see the amyloid plaques in the brain, and to use this information to look at other types of dementia to see if there are differences and/or similarities in the plaques. We will recruit a total of 30 subjects, 10 from each of the following three diagnostic categories: frontotemporal dementia (FTD), Alzheimer's disease, and normal volunteers. All subjects will be given an \[18F\]fluorodeoxyglucose or FDG-PET scan (if they haven't had one in the past) and a PIB-PET scan. The overall objective of this project is to study the biodistribution of 11C-PIB using PET imaging in normal elderly volunteers and relevant patient groups.
Interventions
- RADIATION 11C-PIB PET Scan
- RADIATION FDG-PET Scan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2009-11 |
| Est. Completion | 2021-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00811122
The ClinicalTrials.gov registry entry for NCT00811122 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 11C-PIB PET Scan is the first listed.
NCT00811122 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00811122 about?
NCT00811122 is a clinical study titled "Biodistribution of 11C-PIB PET in Alzheimer's Disease, Frontotemporal Dementia, and Cognitively Normal Elderly". Alzheimer's disease (AD) is characterized by neuritic plaques, neurofibrillary tangles, and neuronal cell loss. Amyloid plaques are believed to play an integral role in AD. Elevated levels of Aβ in the brain are correlated with cognitive decline. There are no approved ways to measure amyloid load i...
What is the current status of trial NCT00811122?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 2 participants. The study started on 2009-11. Estimated completion is 2021-12.
What interventions are being tested in trial NCT00811122?
The interventions under investigation include: 11C-PIB PET Scan (RADIATION), FDG-PET Scan (RADIATION).
Who is sponsoring clinical trial NCT00811122?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.